1628530-41-5Relevant academic research and scientific papers
DOSING OF CABOZANTINIB FORMULATIONS
-
Paragraph 00136, (2015/11/11)
The invention relates to administration of various pharmaceutical formulations of N- (4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metabolites, to achieve des
METABOLITES OF N-(4-{[6,7-BIS(METHYLOXY)QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE
-
, (2014/09/29)
The invention relates to metabolites of cabozantinib (I) as well as uses thereof.
